GiniFFlemingMD

Oncology • Chicago, IL

Breast Cancer, Gynecologic Cancer, Hematologic Oncology

Professor of Medicine, University of Chicago Medicine

Join to view full profile

Dr. Fleming is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fleming's full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Fax+1 773-702-0963

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1988 - 1992
University of ChicagoResidency, Internal Medicine, 1985 - 1987
University of Illinois College of MedicineClass of 1985

Certifications & Licensure

IL State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Chicago Magazine: Top Doctors Castle Connolly, 2006, 2012, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis Start of enrollment: 1996 Jul 01
Completed
Phase 1
Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors Start of enrollment: 1997 Jul 01
Completed
Phase 1
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 1998 Dec 01
Completed
Phase 3
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2000 Sep 18
Completed
Phase 2
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease Start of enrollment: 2002 Mar 01
Completed
Phase 2
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Start of enrollment: 2003 Dec 17
Active, not recruiting
Phase 3
FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer Start of enrollment: 2005 May 01
Withdrawn
Phase 2
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Start of enrollment: 2005 Apr 01
Completed
Phase 2
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 3
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies Start of enrollment: 2007 Aug 01
Completed
Phase 1
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 2
Tumor Gene Expression in Women With Ovarian Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 4
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
Active, not recruiting
Phase 1, Phase 2
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jul 01
Completed
Phase 2
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Completed
Phase 2
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Start of enrollment: 2012 Dec 03
Completed
Phase 2
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 Apr 29
Active, not recruiting
Phase 2
Assessment of Paclitaxel-Induced Neuropathy Start of enrollment: 2013 Aug 29
Active, not recruiting
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2014 Jul 21
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Combining Response and Toxicity Data to Implement Project Optimus.
Robert G Maki, Thomas E Stinchcombe, Gary K Schwartz, Gini F Fleming, Alexia E Iasonos
Journal of Clinical Oncology. 2024-12-10
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Emily Ly, Frederick M Howard, Nan Chen, Olwen Hahn, Gini F Fleming
Journal of Oncology Pharmacy Practice. 2024-12-09
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.
Kun Lin, Elena Michaels, Eric Polley, Peter H O'Donnell, Frederick M Howard
Journal of Oncology Pharmacy Practice. 2024-10-13

Other

Adjuvant treatment of high-risk endometrial cancers
Fleming G, DiSilvestro PA
http://www.uptodate.com/contents/adjuvant-treatment-of-high-risk-endometrial-cancers
UpToDate, Wolters Kluwer Health - 2012-11-13

Press Mentions

Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients with HR-Positive, HER2-Negative Breast Cancer Primary Results from TROPION-Breast01October 29th, 2024
Northwest Indiana Girl Capable of Get Therapy near Residence for Her Uncommon, Aggressive Uterine Most CancersDecember 12th, 2022
ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
Join now to see all

Grant Support

Cancer And Leukemia Group BNational Cancer Institute1999–2008
Core--Protocol And Data ManagementNational Cancer Institute2002
72-Hour Continuous Infusion RhizoxinNational Center For Research Resources1998–2000
5 Fluorouracil &Leucovorin In Cancer Patients With Renal Or Hepatic DysfunctionNational Center For Research Resources1997–2000
Pentostatin In Renal Dysfunction In Cancer PatientsNational Center For Research Resources1997
Phase I Clinical &Pharmacokinetic Study Of Rhizoxin As A 72 Hour InfusionNational Center For Research Resources1996–1997
Phase I Trial Of 5 Ethynyluracil PLUS 5 Fluorouracil For Solid TumorsNational Center For Research Resources1996
5 Fluorouracil &Leucovorin In Patients With Renal Or Hepatic DysfunctionNational Center For Research Resources1996
Effect Of Renal Dysfunction On Pharmacokinetics Of Pentostatin In CancerNational Center For Research Resources1994–1996
Phase II Treatment With Oral All-Trans Retinoic Acid,Interferon, And DoxorubicinNational Center For Research Resources1995
Phase I 5-Fluorouracil &Leucovorin In Patients With Renal Or Hepatic DysfunctionNational Center For Research Resources1994–1995
Comparison Of Dihydropyrimidine Dehydrogenase In Subjects With/Without DiabetesNational Center For Research Resources1994–1995
Phase II Treatment With Oral All-Trans Retinoic Acid, IFN, And DoxorubicinNational Center For Research Resources1994